ANNX

Annexon Inc. (ANNX) | Rumor.io

Annexon

ANNX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,112

Bullish sentiment (50-day avg)84%

Price to earnings ratio-2.99

Market capitalization760.2M

Earnings per share-1.24

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-206.7M

Social

What share of all stock conversation is about ANNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Aug 12

Annexon, Inc.'s ($ANNX) Q2 2026 financial results show a net loss of $55.3m and a cash balance of $209.2m, extending its runway into 2028.
The company is advancing its pipeline, with positive GBS data and BLA submission expected in Q4 2026, and Phase 3 ARCHER II trial on track for Q4 2026.
Annexon's Phase 3 ARCHER II study of vonaprument has been expanded with a 24-month vision-loss endpoint, complementing the 15-month primary endpoint, and topline data remain expected in H2 2026.

Generated by AI

Sentiment

Of the messages about ANNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	92.31%	75% -12.27	50% -33.01
Bearish	0%	7.69%	25% +12.27	50% +33.01

Bullish· Nov 20

$ANNX is projected to reach $1 billion in revenue in the US market for geographic atrophy, with potential for additional revenue in Europe.
Insider buying activity, including a 1.5 million share purchase by a director, suggests confidence in the company's prospects.
The stock's strong momentum and potential for further gains, with target prices of $7.00 and $8.00, make it an attractive long-term investment opportunity.

Bearish· Jun 4

$ANNX is being targeted by short sellers who are spreading false narratives about the company's prospects.
The stock's high volume and heavy float are making it difficult for the price to move, and it's stuck in a range.
The company's warrants and selling pressure from the July 2022 private placement are contributing to the stock's downward momentum.

Generated by AI

Topics

Of the messages about ANNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80.65%	63.78%
Analysts	—	0%	19.35%	24.61%
Technical Analysis	—	0%	0%	11.24%
Earnings	—	0%	0%	0.37%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Jun 4

Annexon's ($ANNX) ANX005 met primary endpoint in pivotal Phase 3 trial for Guillain-Barré Syndrome (GBS), delivering a 2.4-fold improvement in GBS-DS vs. placebo at Week 8.
The trial demonstrated early and sustained improvements in key secondary endpoints, including muscle strength, nerve damage, and ventilation, with patients dosed with 30 mg/kg able to walk independently one month earlier and removed from a ventilator one month sooner.
BofA analyst Tazeen Ahmad raised the firm's price target on Annexon to $12 from $10 and maintains a Buy rating, citing ANX005's single-infusion profile and encouraging efficacy as a differentiated profile with an attractive commercial opportunity.

Generated by AI

Community

Of the messages about ANNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	63.64%	15.7%	56.44%
Newcomers	0%	36.36%	84.3%	43.56%

Regulars· Jun 5

The price of ANNX has dropped 13.36% to $5.19, with a volume of 32k in the last minute.
Annexon, Inc. has commenced an underwritten public offering of $125 million shares of its common stock, impacting the company's stock price.
The trained model forecasts a gloomy future for ANNX, citing a bad short-term setup and a dramatic decline in value.

Newcomers· Jun 5

Investors are taking a long-term view on Annexon, Inc., with a focus on its complement to Sanofi's weak data in cipd, potentially leading to strong data and a sustained cycle.
The stock price of Annexon, Inc. has surged by 21% following its announcement of a $125M public offering with options for underwriters, indicating market interest in the company's plans.
A list of 27 Swedish companies, including Annexon Pharmaceuticals AB, have reported insider transactions, highlighting the activity and potential developments in the industry.

Generated by AI

News

Annexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX)

Annexon bets on functional outcomes in geographic atrophy & GBS; ARCHER II vision endpoints read out in Q4 2026. Click for more on ANNX stock.

3d agoSeeking Alpha

Annexon presents vonaprument data at retina meeting

5d agoInvesting.com

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule

13d agoYahoo Finance UK

Annexon at Cantor Fitzgerald conference: eye data, gbs progress

20d agoInvesting.com

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push

20d agoInvesting.com

Annexon to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9,

27d agoYahoo Finance

Also Discussed

Investors talking about ANNX also mention

#	Name	Attention
1	Alector Inc.ALEC	0%new
2	TERN - Terns Pharmaceuticals, Inc.	——
3	TScan Therapeutics, Inc.TCRX	0%0
4	LVTX - LAVA Therapeutics N.V.	——
5	PMV Pharmaceuticals, Inc.PMVP	0%0
6	Mineralys Therapeutics, Inc.MLYS	0%+0
7	Prime Medicine, Inc.PRME	0%-0.01
8	Arvinas, Inc.ARVN	0%+0
9	Nurix Therapeutics, Inc.NRIX	0%new
10	Vera Therapeutics Inc.VERA	0%new

Annexon Inc.

Healthcare
Biotechnology

Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye. The company’s current pipeline includes investigational medicines for autoimmune, neurodegenerative, neuroimmune, and ophthalmic conditions, with programs designed to block C1q, the initiating molecule of the classical complement pathway. Its product candidates are being studied across areas such as Guillain-Barré syndrome, geographic atrophy, and other serious inflammatory disorders. Annexon’s work centers on complement biology, a mechanism involved in immune activation and tissue damage, giving the company a distinct position within precision immunotherapy research. Headquartered in Brisbane, California, Annexon serves the biotechnology and drug development market through clinical research, translational science, and late-stage therapeutic development.

Website

Location

1400 Sierra Point Parkway

Brisbane, CA, 94005

United States

Social

What share of all stock conversation is about ANNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Aug 12

Annexon, Inc.'s ($ANNX) Q2 2026 financial results show a net loss of $55.3m and a cash balance of $209.2m, extending its runway into 2028.
The company is advancing its pipeline, with positive GBS data and BLA submission expected in Q4 2026, and Phase 3 ARCHER II trial on track for Q4 2026.
Annexon's Phase 3 ARCHER II study of vonaprument has been expanded with a 24-month vision-loss endpoint, complementing the 15-month primary endpoint, and topline data remain expected in H2 2026.

Generated by AI

Sentiment

Of the messages about ANNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	92.31%	75% -12.27	50% -33.01
Bearish	0%	7.69%	25% +12.27	50% +33.01

Bullish· Nov 20

$ANNX is projected to reach $1 billion in revenue in the US market for geographic atrophy, with potential for additional revenue in Europe.
Insider buying activity, including a 1.5 million share purchase by a director, suggests confidence in the company's prospects.
The stock's strong momentum and potential for further gains, with target prices of $7.00 and $8.00, make it an attractive long-term investment opportunity.

Bearish· Jun 4

$ANNX is being targeted by short sellers who are spreading false narratives about the company's prospects.
The stock's high volume and heavy float are making it difficult for the price to move, and it's stuck in a range.
The company's warrants and selling pressure from the July 2022 private placement are contributing to the stock's downward momentum.

Generated by AI

Topics

Of the messages about ANNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80.65%	63.78%
Analysts	—	0%	19.35%	24.61%
Technical Analysis	—	0%	0%	11.24%
Earnings	—	0%	0%	0.37%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Jun 4

Annexon's ($ANNX) ANX005 met primary endpoint in pivotal Phase 3 trial for Guillain-Barré Syndrome (GBS), delivering a 2.4-fold improvement in GBS-DS vs. placebo at Week 8.
The trial demonstrated early and sustained improvements in key secondary endpoints, including muscle strength, nerve damage, and ventilation, with patients dosed with 30 mg/kg able to walk independently one month earlier and removed from a ventilator one month sooner.
BofA analyst Tazeen Ahmad raised the firm's price target on Annexon to $12 from $10 and maintains a Buy rating, citing ANX005's single-infusion profile and encouraging efficacy as a differentiated profile with an attractive commercial opportunity.

Generated by AI

Community

Of the messages about ANNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	63.64%	15.7%	56.44%
Newcomers	0%	36.36%	84.3%	43.56%

Regulars· Jun 5

The price of ANNX has dropped 13.36% to $5.19, with a volume of 32k in the last minute.
Annexon, Inc. has commenced an underwritten public offering of $125 million shares of its common stock, impacting the company's stock price.
The trained model forecasts a gloomy future for ANNX, citing a bad short-term setup and a dramatic decline in value.

Newcomers· Jun 5

Investors are taking a long-term view on Annexon, Inc., with a focus on its complement to Sanofi's weak data in cipd, potentially leading to strong data and a sustained cycle.
The stock price of Annexon, Inc. has surged by 21% following its announcement of a $125M public offering with options for underwriters, indicating market interest in the company's plans.
A list of 27 Swedish companies, including Annexon Pharmaceuticals AB, have reported insider transactions, highlighting the activity and potential developments in the industry.

Generated by AI

Annexon

Social

Aug 12

Bullish· Nov 20

Bearish· Jun 4

Jun 4

Regulars· Jun 5

Newcomers· Jun 5

Annexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX)

Annexon presents vonaprument data at retina meeting

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon at Cantor Fitzgerald conference: eye data, gbs progress

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push

Annexon to Participate in Upcoming September Investor Conferences

Also Discussed

Annexon Inc.

Company Information

Location

Annexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX)

Annexon presents vonaprument data at retina meeting

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon at Cantor Fitzgerald conference: eye data, gbs progress

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push

Annexon to Participate in Upcoming September Investor Conferences

Also Discussed

Social

Aug 12

Bullish· Nov 20

Bearish· Jun 4

Jun 4

Regulars· Jun 5

Newcomers· Jun 5